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Purpose: Prostate cancer is rarely diagnosed in men younger than 40 years of age. At 
present, the available data show a low rate of cancer detection from prostate-specific 
antigen (PSA) screening of this group of young men. We analyzed the outcome of pros-
tate biopsy results in patients of this age group with a high PSA.
Materials and Methods: Between October 1997 and August 2008, a total of 81 men less 
than 40 years of age were referred from the Health Care Promotion Center as the result 
of elevated PSA levels. Six men with prostatitis were excluded. The remaining 75 men 
were asymptomatic and had normal findings on the digital rectal examination (DRE) 
and were selected to have a transrectal ultrasound-guided prostate biopsy for suspected 
prostate cancer. The patients with sustained high PSA levels underwent repeat 
biopsies.
Results: The median age of the 75 men was 33 years (range, 26-40 years) and the mean 
PSA level was 6.57 ng/ml (range, 4.32-13.45 ng/ml). The results of the primary biopsy 
was 1 (1.3%) case of prostate cancer, 70 cases (93%) with benign tissue, 2 cases (2.6%) 
with inflammation, and 1 case each (1.3%) with high grade intraepithelial neoplasia 
(HGPIN) and atypical small acinar proliferation (ASAP). Of the 10 men who underwent 
a second biopsy, all had benign findings. Three of the men who underwent a third biopsy 
all had benign tissue findings.
Conclusions: The prostate cancer detection rate in young men less than 40 years of age 
with high PSA levels and normal DREs was very low. Repeat biopsy for sustained high 
PSA levels in young men less than 40 years of age may not be indicated.
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Prostate-specific antigen (PSA), a single-chain 33 kDa gly-
coprotein serine protease, is produced by the human pros-
tate epithelium only [1,2]. It is the most widely used tumor 
marker for the diagnosis of prostate cancer, which is com-
mon in aging men. More than 80 percent of prostate cancers 
are found in men more than 65 years of age [3]. However, 
due to the broad application of PSA testing, the use of PSA 
screening in younger men has been increasing. According 
to the American Urological Association guidelines of 2009, 
prostate cancer screening is recommended to begin at age 
40 or older in men with a life expectancy of at least 10 years 
[4]. Early prostate cancer screening is especially recom-
mended in cases with high risk, such as African-American 
men and men with a family history [5]. The incidence of 
prostate cancer in men younger than 50 years of age has 
been reported to be approximately 3-4% of the total number 
of prostate cancers [6,7]. The prevalence of prostate cancer 
in 40-59-year-old Korean men is reported to be 0.6% [8]. 
Few studies have evaluated the incidence of prostate can-
cer in young men less than 40 years of age. In our Health 
Care Promotion Center, PSA screening is routinely per-
formed in all men, regardless of age, and prostate biopsy 
is performed in cases with a high PSA level. From this 
screening, men younger than 40 years of age with high PSA 
levels are occasionally detected. The purpose of this study 
was to evaluate the results of the prostate biopsy findings 
in these young men and to determine the clinical sig-
nificance of sustained high PSA levels.Korean J Urol 2010;51:21-24
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TRUS: transrectal ultrasound, HGPIN: high grade prostatic in-
traepithelial neoplasia, ASAP: atypical small acinar proliferation
TABLE 1. Baseline characteristics of the study
Total No. of patients
Mean age (years)
Mean PSA (ng/ml)
No. of follow-up patients
No. of patients with PSA increase
No. of 2nd biopsy patients
No. of 3rd biopsy patients
   75
27.5 (26-40)
6.57 (4.32-13.45)
   44
   15
   10
     3
PSA: prostate-specific antigen
MATERIALS AND METHODS
We retrospectively reviewed data from men with high PSA 
levels (higher than 4.0 ng/ml) who visited the Health 
Promotion Center during the period of October 1997 
through August 2008. We selected samples from men 
younger than 40 years of age with no lower urinary tract 
or prostatitis symptoms. The eligible men underwent a 
routine exam including urine analysis, serum PSA testing, 
and digital rectal examination at our urology department. 
Those who required antibiotic treatment were excluded. In 
the rest of the cases, those with high PSA levels underwent 
transrectal ultrasonography (TRUS) and TRUS-guided 
prostate biopsy. TRUS examination was performed with 
the patients lying on their left side, using BoK 3535 ultra-
sound equipment with a 7 MHz biplane-probe model 8551 
(BoK Medical A/S, Naerum, Denmark). Ultrasound-guid-
ed biopsies were performed with a 1.2 mm core biopsy nee-
dle mounted on a spring-loaded Biopsy Gun (Bard Ltd.) in 
two-dimensional planes (sagittal and axial). Ten core biop-
sies were obtained: 2 cores were taken from each side of the 
lateral and medial part of the base and midpoint, and 1 core 
from each side of the apex. All biopsies were confirmed by 
the pathology department. When the initial biopsy was 
negative, PSA testing was monitored every 6 months. 
Repeat biopsy and magnetic resonance imaging (MRI) of 
the prostate were performed in patients with persistently 
high PSA levels (higher than 4.0 ng/ml).
RESULTS
Seventy-five samples from the 81 men were initially biop-
sied to rule out prostate cancer. The median (range) age of 
the men among the 75 samples was 33 years (range, 26-40 
years), and the mean PSA level of the samples was 6.57 
ng/ml (range, 4.32-13.45 ng/ml). The baseline patient char-
acteristics are shown in Table 1. Seventy-five patients had 
normal findings on a digital rectal examination. After the 
initial biopsy, among the 75 patients, 44 men had follow-up 
PSA testing. The mean period of follow-up was 43 months 
(range, 7-127 months). During the follow-up period, 15 pa-
tients had increased PSA levels (mean, 6.38 ng/ml), where-
as 29 men had decreased PSA levels (mean, 5.42 ng/ml). Of 
44 men, 38 men had a PSA level above 4.0 ng/ml. Ten men 
with sustained high levels of PSA had a second biopsy per-
formed by use of the same method as the initial biopsy. 
Eight men with sustained high levels of PSA had a prostate 
MRI, and three of them had a finding of cancer suspicion. 
A third biopsy was performed in the three men.
Table 2 shows the outcome of the prostate biopsies. For 
the initial biopsy, prostate cancer was detected in one pa-
tient (1.3%). Men with benign prostate tissue accounted for 
93% of the sample (70 men). In addition, there were two cas-
es with inflammation (2.6%), and one each with high grade 
intraepithelial neoplasia (HGPIN) and atypical small aci-
nar proliferation (ASAP) (1.3%). The age of the patient with 
cancer was 30 years, and his PSA level before the biopsy 
was 7.05 ng/ml. The Gleason score from the biopsy was 3+4. 
Due to the localized nature of the prostate cancer, he was 
treated with a radical prostatectomy. Ten men including 
the cases with HGPIN and ASAP underwent a second biop-
sy, and the histological findings showed benign tissue in 
all cases. In the patients with HGPIN and ASAP, the MRI 
findings showed no cancer. Three men underwent a third 
biopsy after a prostate MRI and they were confirmed to 
have benign tissue in all cases.
DISCUSSION
The results of our study showed that the PSA levels of most 
of the samples remained high after the initial PSA testing 
period. Preston et al reported that the mean serum PSA lev-
els of Caucasian males 20-29 and 30-39 years of age were 
0.47 ng/ml and 0.55 ng/ml, respectively [9]. Among African 
Americans, the mean serum PSA levels of the same two age 
groups were 0.51 ng/ml and 0.57 ng/ml. Ku et al reported 
that the median serum PSA levels of Korean young men 
were 0.90 ng/ml for the 20-29-year-old age group and 0.89 
ng/ml for the 30-39-year-old age group [10]. In these two 
studies, there were no young men with high PSA levels who 
underwent prostate biopsy.
The factors causing an increase in PSA levels among 
men in young age groups are not well defined. Several in-
vestigations have reported PSA levels in relation to age, di-
et manipulation, obesity, and ethnicity [11-15]. However, 
the risks associated with all such factors remain contro-
versial. Increased PSA levels are considered to be a pre-
malignant finding or to signify the presence of a small in-
filtrating carcinoma that has not yet become clinically evi-
dent [16,17]. Alternatively, an initially increased PSA level Korean J Urol 2010;51:21-24
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may be associated with elevated androgen secretion, which 
causes an increased PSA level that might influence the sub-
sequent development of prostate cancer [17]. At present, 
there are no guidelines for cancer detection in men less than 
40 years of age on the basis of increased PSA levels.
The results of our retrospective study on increased PSA 
levels in men less than 40 years of age showed that only 
1.3% of the patients had prostate cancer. Ruska et al re-
ported data on 87 men younger than 40 years of age who 
underwent prostate needle biopsy; 23 of them were found 
to have prostate cancer [18]. The most common reason for 
a biopsy was an abnormal digital rectal examination. 
However, confirmation of prostate cancer in younger men 
is difficult because PSA testing is not routinely performed 
in young men.
In our study, the 75 men studied were asymptomatic; 
they only had high PSA levels, and their digital rectal ex-
amination (DRE) examinations were normal. The results 
of our study suggest that PSA alone, in this age group, was 
not effective for detecting prostate cancer. According to our 
findings, the cancer detection rate from PSA screening was 
very low. In an effort to optimize the ability of serum PSA 
to perform as an ideal marker for the detection of cancer 
among young men, the characteristics of serum PSA values 
in young men require further study.
Histology examinations were also performed. HGPIN 
and ASAP were detected in 1.3% of our initial biopsy 
results. Roscigno et al reported on the incidence of HGPIN 
(0.6-24.6%) and ASAP (0.7-23.4%) in initial biopsy results 
[19]. The risk of developing cancer from HGPIN is 31.5% 
and the risk from ASAP is 40% after repeat biopsies [19]. 
In our two cases of HGPIN and ASAP, the results of a second 
biopsy confirmed only benign tissue. The multifocality of 
HGPIN and ASAP has been associated with a greater risk 
of prostate adenocarcinoma [20]. However, the results of 
our cases showed only unifocality in both HGPIN and 
ASAP samples. The MRI evaluation of HGPIN and ASAP 
was not suspicious for cancer. The clinical significance of 
HGPIN and ASAP in young men is unclear.
Performance of repeat biopsy and prostate MRI on pa-
tients with persistently high PSA levels has both risks and 
benefits for the early detection of prostate cancer. Conside-
ration of the invasiveness, pain, and high cost of these pro-
cedures is important. The possibility of false-negative find-
ings for cancer detection has been reported to be 82% in the 
age group less than 60 and 65% for men more than 60. The 
likelihood of detecting cancer on repeat biopsy is reported 
to be 10% [21]. Prostate cancer detection by MRI shows a 
wide range (from 50% to 92%) of accuracy [22]. Despite the 
high specificity of MRI, the routine use of MRI for prostate 
cancer detection remains controversial because of its low 
sensitivity and substantial interobserver variability [23]. 
In our study, the MRI findings did not match the results 
of the prostate biopsy. Based on the negative results of our 
repeat biopsies and prostate MRIs, performance of repeat 
biopsies in young men with persistently high PSA levels 
may not provide any benefit for the early detection of pros-
tate cancer.
The limitations of this study include the following. Not 
all of the men with PSA elevation were followed up after 
the initial biopsy. In addition, the number of cases avail-
able for repeat biopsy and prostate MRI was very small. 
Finally, this was a retrospective study.
CONCLUSIONS
The results of this study show that prostate cancer de-
tection in young men less than 40 years of age with high 
PSA levels and normal DREs was very low. The role of re-
peat biopsy and diagnostic MRI for persistently high levels 
of PSA in this age group is uncertain given the negative 
pathology results in all cases. Accordingly, repeat biopsy 
for persistently high PSA levels with normal DRE findings 
in men younger than 40 years of age may not be indicated. 
Additional large, prospective randomized trials are needed 
to confirm our findings.
REFERENCES
1. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of 
a human prostate specific antigen. Invest Urol 1979;17:159-63.
2. Sensabaugh GF. Isolation and characterization of a se-
men-specific protein from human seminal plasma: a potential 
new marker for semen identification. J Forensic Sci 1978;23: 
106-15.
3. Boyle P, Severi G, Giles GG. The epidemiology of prostate cancer. 
Urol Clin North Am 2003;30:209-17.
4. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han 
M, et al. Prostate specific antigen best practice statement: 2009 
update. J Urol 2009;182:2232-41.
5. Smith RA, Cokkinides V, von Eschenbach AC, Levin B, Cohen C, 
Runowicz CD, et al. American Cancer Society guidelines for the 
early detection of cancer. CA Cancer J Clin 2002;52:8-22.
6. Sacco E, Prayer-Galetti T, Pinto F, Ciaccia M, Fracalanza S, Betto 
G, et al. Familial and hereditary prostate cancer by definition in 
an Italian surgical series: clinical features and outcome. Eur Urol 
2005;47:761-8.
7. Azzouzi AR, Valeri A, Cormier L, Fournier G, Mangin P, Cussenot 
O. Familial prostate cancer cases before and after radical prosta-
tectomy do not show any aggressiveness compared with sporadic 
cases. Urology 2003;61:1193-7.
8. Lee HW, Kwak KW, Choi YH, Choi HY, Lee HM. New thresholds 
for prostate-specific antigen velocity for prostate cancer screen-
ing in Korean patients younger than 60 years old. Korean J Urol 
2008;49:113-7.
9. Preston DM, Levin LI, Jacobson DJ, Jacobsen SJ, Rubertone M, 
Holmes E, et al. Prostate-specific antigen levels in young white 
and black men 20 to 45 years old. Urology 2000;56:812-6.
10. Ku JH, Ahn JO, Lee CH, Lee NK, Park YH, Byun SS, et al. 
Distribution of serum prostate-specific antigen in healthy Korean 
men: influence of ethnicity. Urology 2002;60:475-9.
11. Oesterling JE, Kumamoto Y, Tsukamoto T, Girman CJ, Guess 
HA, Masumori N, et al. Serum prostate-specific antigen in a com-
munity-based population of healthy Japanese men: lower values 
than for similarly aged white men. Br J Urol 1995;75:347-53.
12. Freedland SJ, Terris MK, Platz EA, Presti JC Jr. Body mass index 
as a predictor of prostate cancer: development versus detection Korean J Urol 2010;51:21-24
24 Yang et al
on biopsy. Urology 2005;66:108-13.
13. Chung BH, Hong SJ, Cho JS, Seong DH. Relationship between 
serum prostate-specific antigen and prostate volume in Korean 
men with benign prostatic hyperplasia: a multicentre study. BJU 
Int 2006;97:742-6.
14. Kobayashi T, Kinoshita H, Nishizawa K, Mitsumori K, Ogawa O, 
Kamoto T. Age-associated increase of prostate-specific antigen in 
a high level of men visiting urological clinics. Int J Urol 2005; 
12:733-8.
15. Bray GA. The underlying basis for obesity: relationship to cancer. 
J Nutr 2002;132(11 Suppl):3451S-5.
16. Antenor JA, Han M, Roehl KA, Nadler RB, Catalona WJ. 
Relationship between initial prostate specific antigen level and 
subsequent prostate cancer detection in a longitudinal screening 
study. J Urol 2004;172:90-3.
17. Fang J, Metter EJ, Landis P, Chan DW, Morrell CH, Carter HB. 
Low levels of prostate-specific antigen predict long-term risk of 
prostate cancer: results from the Baltimore Longitudinal Study 
of Aging. Urology 2001;58:411-6.
18. Ruska KM, Partin AW, Epstein JI, Kahane H. Adenocarcinoma 
of the prostate in men younger than 40 years of age: diagnosis and 
treatment with emphasis on radical prostatectomy findings. 
Urology 1999;53:1179-83.
19. Roscigno M, Scattoni V, Freschi M, Raber M, Colombo R, Bertini 
R, et al. Monofocal and plurifocal high-grade prostatic intra-
epithelial neoplasia on extended prostate biopsies: factors pre-
dicting cancer detection on extended repeat biopsy. Urology 
2004;63:1105-10.
20. Epstein Jl, Herawi M. Prostate needle biopsies containing pro-
static intraepithelial neoplasia or atypical foci suspicious for car-
cinoma: implications for patient care. J Urol 2006;175:820-34.
21. Djavan B, Zlotta A, Remzi M, Ghawidel K, Basharkhah A, 
Schulman CC, et al. Optimal predictors of prostate cancer on re-
peat prostate biopsy: a prospective study of 1,051 men. J Urol 
2000;163:1144-8.
22. Engelbrecht MR, Jager GJ, Laheij RJ, Verbeek AL, van Lier HJ, 
Barentsz JO. Local staging of prostate cancer using magnetic res-
onance imaging: a meta-analysis. Eur Radiol 2002;12:2294-302.
23. Hricak H. MR imaging and MR spectroscopic imaging in the 
pre-treatment evaluation of prostate cancer. Br J Radiol 2005; 
78:S103-11.